The outcome of children with acute myeloid leukemia (AML) post-allogeneic stem cell transplantation (SCT) is not improved by the addition of etoposide to the conditioning regimen

Pediatric Blood and Cancer

Volumn 47, Issue 7, 2006, Pages 926-930

  Ayas, Mouhab ^a   Al Seraihi, Amal ^a   Al Mahr, Mohamad ^a   Al Jefri, Abdullah ^a   Belgaumi, Assim ^a   Elhassan, Ibrahim ^a   El Solh, Hassan ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Acute myeloid leukemia; Etoposide; Stem cell transplantation

Indexed keywords

BLEOMYCIN; BUSULFAN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK; SKIN TOXICITY; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; NEOPLASMS, SECOND PRIMARY; RECURRENCE; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33750441845     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20758     Document Type: Article

References (25)

1. Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: A report from the Children's Cancer Group. Blood 2001;97:56-62.
2. Amadori S, Testi AM, Arico M, et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. J Clin Oncol 1993;11:1046-1054.
3. Michel G, Leverger G, Leblanc T, et al. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Bone Marrow Transplant 1996;17:191-196.
4. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compare with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1996;334:1428-1434.
5. Nesbit ME, Buckley JD, Feig SA, et al. Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: A report from the Children's Cancer Group. J Clin Oncol 1994;12:127-135.
6. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regime. Blood 1987;70:1382-1388.
7. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983;309:1347-1353.
8. Linker AC, Ries CA, Damon LE, et al. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood 1993;81:311-318.
9. Blume KG, Forman SJ, O'Donnell MR, et al. Total body irradiation and high dose etoposide: A new regimen for bone marrow transplantation for patients with advanced hematologic malignancies. Blood 1987;69:1015-1020.
10. Snyder DS, Chao NJ, Amylon MD, et al. Fractionated total body irradiation and high dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. Blood 1993;82:2920-2928.
11. Kanda Y, Akiyama H, Tanikawa S, et al. Etoposide with/without G-CSF with busulfan and cyclophosphamide for bone marrow transplantation. The BMT team. Am J Hematol 1996;51:265-268.
12. Kröger N, Zabelina T, Sonnenberg S, et al. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. Bone marrow transplant 2000;26:711-716.
13. Zander AR, Berger C, Kroger N, et al. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Clin cancer res 1997;3:2671-2675.
14. Stadtmauer EA, Cassileth PA, Gale RP. Etoposide in leukemia, lymphoma and bone marrow transplantation. Leuk Res 1989;13:639-650.
15. Chang T, Gulati S, Chou T, et al. Synergistic effect of 4-hydroxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis. Cancer Res 1985;45:2234-2339.
16. Tallman MS, Rowlings PA, Milone G, et al. Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood 2000;96:1254-1258.
17. Cahn JY, Labopin M, Sierra J, et al. No impact of high dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute leukaemia Working Party of the European Group for Blood ad Marrow Transplantation (EBMT). Br J Haematol 2000;110:308-314.
18. Robin M, Guardiola P, Dombret H, et al. Allogeneic bone marrow transplantation for acute myeloblastic leukaemia in remission: Risk factors for long-term morbidity and mortality. Bone Marrow Transplant 2003;31:877-887.
19. Clift RA, Buckner D, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens. Blood 1990;76:1867-1871.
20. Clift RA, Buckner D, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens. Blood 1991;77:1660-1665.
21. Duerst RE, Horan JT, Leisveld JL, et al. Allogeneic bone marrow transplantation for children with acute leukemia: Cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide. Bone marrow transplant 2000;25:489-494.
22. Sandler ES, Hagg R, Coppes MJ, et al. Hematopoietic stem cell transplantation with a conditioning regimen of busulfan, cyclophosphamide and etoposide for children with acute myelogenous leukemia (AML): A phase I study of the Pediatric Blood and Marrow Transplant Consortium. Med Pediatr Oncol 2000;35:403-409.
23. Farag SS, Bolwell BJ, Elder PJ, et al. High dose busulfan, cyclophosphamide and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia. Bone marrow tranplant 2005;35:653-661.
24. Felix CA. Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol 2001;36:525-535.
25. Felix CA, Blatt J. Etoposide and Langerhans cell histiocytosis: Second malignancies, a second look. Pediatr Hematol Oncol 1999;16:183-185.